Valuation : Endonovo Therapeutics, Inc.

Market Cap 2.77M 2.39M 2.24M 2.05M 3.85M 265M 3.87M 26.58M 10.37M 134M 10.41M 10.19M 444M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.55M 8.02M 7.32M 13.79M 949M 13.84M 95.15M 37.12M 479M 37.27M 36.46M 1.59B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day-50.00%
Current month+9,900.00%
1 month+9,900.00%
6 months+100.00%
1 week 0
Extreme 5.0E-5
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.02
5 years 0
Extreme 1.0E-6
0.06
10 years 0
Extreme 1.0E-6
170
Manager TitleAgeSince
Chief Executive Officer 61 2012-02-29
Investor Relations Contact - 2014-04-30
Corporate Officer/Principal 77 2022-11-29
Director TitleAgeSince
Chairman 61 2012-02-29
Date Insider Type Main position Quantity % Market Cap.
6/30/20 Buy

Chief Executive Officer

400 0.0045%
2/21/20 Buy

Chief Executive Officer

100 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%0.00%-50.00%-99.22% 90.38K
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -6.82%-6.73%+48.38%+163.24% 28.19B
Weighted average by Cap. -1.93%-1.50%+57.15%+152.82%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.99 0.1 0.7 0.27 3.53 0.27 0.27 11.69 0.14 0.12 0.11 0.1 0.19 12.94 0.19 1.3 0.51 6.53 0.51 0.5 21.65
Net income -3.1M -2.68M -2.51M -2.29M -4.31M -297M -4.33M -29.76M -11.61M -150M -11.66M -11.4M -497M -18.47M -15.92M -14.93M -13.63M -25.67M -1.77B -25.75M -177M -69.09M -891M -69.36M -67.85M -2.96B
Net Debt 7.1M 6.11M 5.73M 5.23M 9.86M 678M 9.89M 68.01M 26.54M 342M 26.64M 26.06M 1.14B 7.15M 6.16M 5.78M 5.28M 9.94M 684M 9.97M 68.57M 26.75M 345M 26.86M 26.27M 1.14B
Logo Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
1
Date Price Change Volume
26-08-28 US$0.000050 -50.00% 999,999
26-08-26 US$0.000100 0.00% 500,000
26-08-24 US$0.000100 0.00% 1,499,999
26-08-21 US$0.000100 0.00% 999,999
  1. Stock Market
  2. Stocks
  3. ENDV Stock